Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about DMRA, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| DMR-001 | Myeloproliferative Neoplasms (MPNs) | Phase 1 · NCT07849231 | Recruiting |
Also used in these trials (approved or third-party drugs, not DMRA's own candidates): Ruxolitinib.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
DMRA holds $528.5M in cash and short-term investments (as of Sep 30, 2026) and burns about $19.6M/quarter from operations, an estimated runway of 81.1 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 0 · Low
Based on current estimates of our expenses going forward, we believe that our existing cash, cash equivalents and marketable securities of $528.5 million as of September 30, 2026 will be sufficient to fund our operations into the second half of 2029.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when DMRA files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Fairmount Funds Management LLC Director, 10% owner · +37,887 options |
Insider | 8,713,000 | 14.07% | 2026-02-09 |
| Avoro Capital Advisors LLC | Institution (13G, 5%+) | 3,783,000 | 6.11% | 2026-03-31 |
| Venrock Healthcare Capital Partners III, | 5%+ holder (13G) | 3,603,595 | 5.82% | 2026-02-09 |
| BlackRock, Inc. | Institution (13G, 5%+) | 3,143,576 | 5.08% | 2026-06-30 |
| Jennifer Jarrett Director, President and CEO, Director · +1.50M options |
Insider | 512,500 | 0.83% | 2026-09-25 |
| L. Becker Hewes Chief Medical Officer · +528,603 options |
Insider | 264,629 | 0.43% | 2026-01-05 |
| FMR LLC | Institution (13G, 5%+) | 238,878 | 0.39% | 2025-11-28 |
| Sherwin Sattarzadeh Chief Operating Officer · +444,209 options |
Insider | 190,376 | 0.31% | 2026-01-05 |
| Julianne Bruno Director · +37,313 options |
Insider | 137,032 | 0.22% | 2026-02-09 |
| Hans T. Schambye Chief Executive Officer, Director · +19,040 options |
Insider | 4,682 | 0.01% | 2026-01-02 |
| Garrett Winslow General Counsel · +256,640 options |
Insider | 2,289 | 0.00% | 2026-07-03 |
| Lori Firmani Chief Financial Officer · +5,726 options |
Insider | 931 | 0.00% | 2026-01-02 |
Share count 61,904,742 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for DMRA and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →